ISRCTN12680338已完成未知
Arthritis prevention in the pre-clinical phase of rheumatoid arthritis with abatacept long-term outcome study
Kings College London and Guy's and St Thomas' NHS Foundation Trust0 个研究点目标入组 143 人开始时间: 2020年4月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 143
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 20/07/2021:
- •1. Male or female participants, aged =18 years.
- •2. All participants deemed eligible and randomised to the APIPPRA study.
- •3. All participants who completed at least one APIPPRA study visit.
- •4. All participants who are willing to give written informed consent and comply with the requirements of the ALTO study protocol.
- •Previous inclusion criteria:
- •1. Male or female participants, aged =18 years
- •2. All participants deemed eligible and randomised to the APIPPRA study
- •3. All participants who completed at least one APIPPRA study visit
- •4. All participants who are willing to consent to the ALTO study
排除标准
- •1. Participants who are still participating in the APIPPRA study
- •2. Participants ineligible and randomised to the APIPPRA study in error
- •3. Participants deemed eligible and randomised to the APIPPRA study but who never received study drug
- •4. Those unable to give informed consent
研究者
相似试验
进行中（未招募）
1 期
Arthritis prevention with abataceptThe target population for therapeutic intervention will be subjects who carry serum autoantibodies (antibodies to citrullinated protein antigens – ACPArheumatoid factor – RF) and who have joint pains (arthralgia) but no joint swelling. These subjects are deemed to be at highest risk of developing rheumatoid arthritis.MedDRA version: 20.0Level: PTClassification code 10003239Term: ArthralgiaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-003413-18-NLeiden University Medical Center206
已完成
2 期
Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept.gewrichsaandoeningenArthralgiaReumatoid Arthritis10003816NL-OMON47610eids Universitair Medisch Centrum20
进行中（未招募）
1 期
Arthritis prevention with abataceptThe target population for therapeutic intervention will be subjects who carry serum autoantibodies (antibodies to citrullinated protein antigens – ACPArheumatoid factor – RF) and who have joint pains (arthralgia) but no joint swelling. These subjects are deemed to be at highest risk of developing rheumatoid arthritis.MedDRA version: 20.0 Level: PT Classification code 10003239 Term: Arthralgia System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-003413-18-GBKing’s College London206
已完成
不适用
Arthritis Prevention In the Pre-clinical Phase of Rheumatoid Arthritis with AbataceptTopic: Musculoskeletal disordersSubtopic: Musculoskeletal (all Subtopics)Disease: MusculoskeletalMusculoskeletal DiseasesISRCTN46017566Guy's and St Thomas' NHS Foundation Trust213
已完成
不适用
STRategies in Early Arthritis ManagementPolyarthritis/rheumatoid arthritisMusculoskeletal DiseasesOther rheumatoid arthritisISRCTN56637846Jan van Breemen Institute (Netherlands)80